FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C	20549	
vasilligion,	D.C.	20049	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Bjork Elisabeth</u>					RO	2. Issuer Name and Ticker or Trading Symbol ROCKET PHARMACEUTICALS, INC. [RCKT]								eck all appli	cable)	ing Person(s) to Iss 10% Ow Other (s		vner	
(Last) (First) (Middle) C/O ROCKET PHARMACEUTICALS, INC. 9 CEDARBROOK DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 06/22/2023									(give title		below)	pecity		
				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) CRANBURY NJ 08512														X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				ction 2A. Deemed Execution Date,			3. Transactic Code (Ins	tion Disposed Of (D)		ties Acquired (A) or l Of (D) (Instr. 3, 4 and		Benefici Owned F	es ally Following	Form:	: Direct C Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership			
							Code	/ Amo	unt	(A) o (D)	Price	Transact	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	n 3A. Deemed 4. Execution Date, Transa		Fransact Code (In	insaction of			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				C	Code	v	(A)	(D)	Date Exercisable	Expiration Date	on	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$21.56	06/22/2023			A		25,850		(1)	06/22/20)33	Common Stock	25,850	\$0	25,850		D		
Stock Option (Right to Buy)	\$21.56	06/22/2023			A		3,590		(2)	06/22/20)33	Common Stock	3,590	\$13.93	3,590		D		

Explanation of Responses:

- 1. This option represents a right to purchase a total of 25,850 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024.
- 2. This option represents a right to purchase a total of 3,590 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024. This option was issued to the Reporting Person in lieu of director retainer fees of \$50,000.

/s/ Martin Wilson, as attorney-

06/26/2023

in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.